

# ACTIVE CLINICAL TRIAL IN RENAL CELL CARCINOMA



PHASE 3 (NCT03729245)

## PIVOT-09: Bempegaldesleukin plus nivolumab in patients with advanced renal cell carcinoma

A randomized study of bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) compared with the investigator's choice of tyrosine kinase inhibitor therapy (either sunitinib or cabozantinib) for previously untreated advanced renal cell carcinoma

Scan here to find out more about this clinical study at [ClinicalTrials.gov](https://ClinicalTrials.gov)



### POPULATION

- Previously untreated advanced renal cell carcinoma
- Any IMDC prognostic score
- Tumor tissue available for PD-L1 testing

N=623

R

BEMPEG + NIVO

Investigator's choice of  
**sunitinib** or **cabozantinib**

### CO-PRIMARY ENDPOINTS

- Objective response rate
- Overall survival

### KEY SECONDARY ENDPOINTS

- Progression-free survival
- Safety and tolerability

Bempegaldesleukin is an investigational CD122-preferential IL-2-pathway agonist<sup>2</sup>

Nivolumab is a PD-1 blocking antibody<sup>3</sup>

BEMPEG, bempegaldesleukin (NKTR-214); IL-2, interleukin-2; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; NIVO, nivolumab; PD-1, programmed death-1; PD-L1, programmed death-ligand 1.

1. [ClinicalTrials.gov](https://ClinicalTrials.gov). NCT03729245. <https://clinicaltrials.gov/ct2/show/NCT03729245>. Accessed March 10, 2021; 2. Bentebibel SE, et al. *Cancer Discov* 2019;9:711-21;

3. Opdivo (nivolumab) Prescribing Information (Princeton, NJ: Bristol Myers Squibb; revised: January 2021).

# ACTIVE CLINICAL TRIALS WITH BEMPEGALDESLEUKIN AND NIVOLUMAB


NEKTAR

Bristol Myers Squibb™

Bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) leverages two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with cancer

**FIND OUT MORE**

Scan here to discover more about BEMPEG at Nektar.com



<sup>a</sup>Neoadjuvant and adjuvant setting.

BEMPEG, bempegaldesleukin (NKTR-214); NIVO, nivolumab; R/R, relapsed/refractory

**FOR EDUCATIONAL PURPOSES ONLY.**

This compound and the combination of agents and their uses have not been approved.

Nektar Therapeutics, 455 Mission Bay Boulevard South, San Francisco, California 94158. Copyright Nektar Therapeutics © 2021. All rights reserved.

MED--2000001\_2021JUL12